Sequential Fibroblast Growth Factor Receptor Inhibition in Intrahepatic Cholangiocarcinoma: Navigating an Evolving Landscape of Resistance and Opportunity-A Case Report and Current Opinion [0.03%]
肝内胆管癌的序贯成纤维细胞生长因子受体抑制：克服耐药性并抓住机遇——一例报告和综述
Hideki Sasanuma,Hironori Yamaguchi
Hideki Sasanuma
Fibroblast growth factor receptor (FGFR)2 rearrangements define a distinct molecular subset of intrahepatic cholangiocarcinoma (iCCA) with therapeutic potential using FGFR inhibitors. However, acquired resistance invariably limits long-term...
Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast [0.03%]
恩沃卢单抗联合帕博利珠单抗治疗初治局部晚期或转移性尿路上皮癌的治疗优化及不良事件管理：播客节目
Thomas Powles,Maria Lapuente,Benjamin Garmezy
Thomas Powles
In the EV-302/KEYNOTE-A39 trial (NCT04223856), enfortumab vedotin + pembrolizumab (EV + P) became the first treatment in decades to demonstrate significant survival benefit compared with platinum-based chemotherapy in the first-line setting...
Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study [0.03%]
免疫检查点抑制剂治疗转移性非小细胞肺癌的无进展生存期：一项回顾性队列研究
Paul Boré,Margaux Geier,Loïc Campion et al.
Paul Boré et al.
Introduction: Immune checkpoint inhibitors (ICI) are the standard of care for non-small-cell lung cancer (NSCLC) regardless of program death ligand-1 (PDL1) expression. However, a majority of patients presented early prog...
A Real-World Retrospective Observational Study of Patients with Advanced/Recurrent Endometrial Cancer Across England [0.03%]
英格兰晚期/复发性子宫内膜癌患者的现实回顾性观察研究
Jamie Wallis,Shammi Luhar,Filipa Tunaru et al.
Jamie Wallis et al.
Introduction: Robust real-world data (RWD) on endometrial cancer (EC) are lacking. In the United Kingdom (UK), molecular classification of EC based on tumour mismatch repair (MMR) status, either MMR-deficient (dMMR) or MM...
The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium [0.03%]
比利时使用抗PD-1制剂治疗早期癌症的健康影响
André Bento-Abreu,Saar Vandekeere,Demet Sönmez et al.
André Bento-Abreu et al.
Introduction: Anti-PD-1 agents, inhibitors of programmed cell death protein 1 (PD-1), significantly improve clinical outcomes and overall survival for individuals with several metastatic and early-stage cancers. This stud...
Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China [0.03%]
brigatinib与alectinib一线治疗中国alk阳性晚期非小细胞肺癌的药物经济学分析
Qingqing Chai,Congling Gu,Luis Hernandez et al.
Qingqing Chai et al.
Introduction: Brigatinib and alectinib are anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (ALK-TKIs) approved in China in 2022 and 2018, respectively, for the treatment of patients with ALK-positive, advanced...
Integration of Palliative Care as a Part of the Multidisciplinary Management of Patients with Head and Neck Cancer [0.03%]
多学科头颈部肿瘤综合治疗中姑息治疗的整合
Antti Mäkitie,Tiina Saarto
Antti Mäkitie
Clinical Outcome of Febrile Neutropenia and Associated Factors Among Adult Patients with Cancer Treated at Ethiopian Oncology Centers: A Retrospective Observational Study [0.03%]
埃塞俄比亚肿瘤治疗中心成人癌症患者发热性中性粒细胞减少的临床结局及其相关因素：回顾性观察研究
Samuel Agegnew Wondm,Getachew Yitayew Tarekegn,Fisseha Nigussie Dagnew et al.
Samuel Agegnew Wondm et al.
Introduction: Febrile neutropenia (FN) is a major cause of dose-limiting complications in cancer treatment that predisposes patients to serious infections. Despite advancements in therapies, including empirical and defini...
Real-World Quantitative Insights into the Treatment Experience of Patients with Cancer in the USA with Subcutaneous Versus Intravenous Drug Delivery [0.03%]
美国癌症患者皮下注射与静脉输注药物治疗的现实世界定量分析
Robert Epstein,JoAnn Krenitsky,Phillip Sarocco
Robert Epstein
Introduction: While oncology treatments have traditionally been delivered through the intravenous (IV) route of administration (ROA), subcutaneous (SC) alternatives have become increasingly available. Research comparing r...
Kalé Kponee-Shovein,Vimalanand S Prabhu,Yan Song et al.
Kalé Kponee-Shovein et al.
Introduction: Disease-free survival (DFS) is commonly a primary endpoint in clinical trials of investigational therapies for early stage and/or high-risk endometrial cancer and may be indicative of therapeutic benefit pri...